TrialAnnals of the rheumatic diseases2015

Safety and efficacy of baricitinib at 24 weeks in patients with rheumatoid arthritis who have had an inadequate response to methotrexate.

Edward C Keystone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.